Treatment of recurrent aphthous stomatitis (RAS; aphthae; canker sores) with a barrier forming mouth rinse or topical gel formulation containing hyaluronic acid: a retrospective clinical study.
Barrier forming
Hyaluronic acid
Recurrent aphthous stomatitis
Rinse
Topical gel
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
16 07 2019
16 07 2019
Historique:
received:
15
03
2019
accepted:
09
07
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
20
11
2019
Statut:
epublish
Résumé
Use of hyaluronic acid-based products has become a valuable alternative to drug-based approaches in the treatment of recurrent aphthous stomatitis (RAS). The presented study aimed to investigate the effect of a barrier forming hyaluronic acid containing mouth wash or a topical gel formulation on the healing of RAS and patient's quality of life. For this single-center retrospective study, medical records of the Dental School of the University of Brescia were screened for adult and systemically health patients suffering from minor recurrent aphthous stomatitis (RAS) and treated with either a barrier forming, hyaluronic acid containing mouth wash (GUM® AftaClear® rinse) or a topical gel (GUM® AftaClear® gel) in 2015. All patients fulfilling the in-/exclusion criteria and presenting full data sets on lesion diameter, lesion color, as well as pain perception for baseline (day 0) and 4 and 7 days after treatment were enrolled into the presented study. Out of 60 screened patients, a total of 20 patients treated with the Rinse formulation and 25 treated with the Gel formulation were eligible for the enrollment into this study. Both groups showed equal distribution in patient's age, sex and presented a similar mean lesion size (3.0 ± 1.0 mm), lesion color distribution as well as pain perception at baseline. All patients showed significant normalization of lesion color, reduction of pain, and lesion dimension within the course of their treatment. After 7 days, the mean percentage of lesion reduction was highly significant for both groups attaining 77.4 ± 30.1% in the Rinse group and 81.2 ± 23.1% in the Gel group with a complete lesion closure obtained in 60 and 56% of the cases, respectively. However, a significant (p < 0.05) higher percentage of lesions in the Gel group (72%) compared to the Rinse group (40%) showed an improvement in lesion size already after 3 days. Within the limitation of retrospective design, it can be concluded that both the barrier forming hyaluronic acid containing mouth rinse as well as the topical gel formulation are effective in the treatment of minor recurrent aphthous stomatitis (RAS), with a trend for an earlier healing onset for the topical Gel formulation.
Sections du résumé
BACKGROUND
Use of hyaluronic acid-based products has become a valuable alternative to drug-based approaches in the treatment of recurrent aphthous stomatitis (RAS). The presented study aimed to investigate the effect of a barrier forming hyaluronic acid containing mouth wash or a topical gel formulation on the healing of RAS and patient's quality of life.
METHODS
For this single-center retrospective study, medical records of the Dental School of the University of Brescia were screened for adult and systemically health patients suffering from minor recurrent aphthous stomatitis (RAS) and treated with either a barrier forming, hyaluronic acid containing mouth wash (GUM® AftaClear® rinse) or a topical gel (GUM® AftaClear® gel) in 2015. All patients fulfilling the in-/exclusion criteria and presenting full data sets on lesion diameter, lesion color, as well as pain perception for baseline (day 0) and 4 and 7 days after treatment were enrolled into the presented study.
RESULTS
Out of 60 screened patients, a total of 20 patients treated with the Rinse formulation and 25 treated with the Gel formulation were eligible for the enrollment into this study. Both groups showed equal distribution in patient's age, sex and presented a similar mean lesion size (3.0 ± 1.0 mm), lesion color distribution as well as pain perception at baseline. All patients showed significant normalization of lesion color, reduction of pain, and lesion dimension within the course of their treatment. After 7 days, the mean percentage of lesion reduction was highly significant for both groups attaining 77.4 ± 30.1% in the Rinse group and 81.2 ± 23.1% in the Gel group with a complete lesion closure obtained in 60 and 56% of the cases, respectively. However, a significant (p < 0.05) higher percentage of lesions in the Gel group (72%) compared to the Rinse group (40%) showed an improvement in lesion size already after 3 days.
CONCLUSIONS
Within the limitation of retrospective design, it can be concluded that both the barrier forming hyaluronic acid containing mouth rinse as well as the topical gel formulation are effective in the treatment of minor recurrent aphthous stomatitis (RAS), with a trend for an earlier healing onset for the topical Gel formulation.
Identifiants
pubmed: 31311529
doi: 10.1186/s12903-019-0850-1
pii: 10.1186/s12903-019-0850-1
pmc: PMC6636158
doi:
Substances chimiques
Mouthwashes
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
153Références
Arch Immunol Ther Exp (Warsz). 2014 Jun;62(3):205-15
pubmed: 24217985
J Oral Pathol Med. 2006 Sep;35(8):461-5
pubmed: 16918596
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Apr;89(4):425-31
pubmed: 10760725
GMHC Treat Issues. 1995 Nov;9(11):12
pubmed: 11362988
Drugs. 2001;61(6):777-87
pubmed: 11398909
Prim Dent J. 2016 Feb 1;5(1):30-33
pubmed: 29029650
Ann Dermatol Venereol. 2001 Dec;128(12):1327-9
pubmed: 11908135
Br J Oral Maxillofac Surg. 2008 Apr;46(3):198-206
pubmed: 17850936
Clin Exp Rheumatol. 1999 May-Jun;17(3):393
pubmed: 10410284
Stat Med. 2007 Aug 30;26(19):3661-75
pubmed: 17315184
J Clin Exp Dent. 2014 Dec 01;6(5):e535-8
pubmed: 25674322
J Eur Acad Dermatol Venereol. 2008 May;22(5):590-5
pubmed: 18093111
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Feb;81(2):141-7
pubmed: 8665304
Quintessence Int. 1990 Feb;21(2):141-51
pubmed: 2197661
J Oral Pathol Med. 1992 Jan;21(1):21-5
pubmed: 1593490
J Biol Regul Homeost Agents. 2017 Dec 04;31(4 Suppl 2):63-69
pubmed: 29202564
Pain Manag Nurs. 2015 Jun;16(3):182-7
pubmed: 26025792
Med Oral Patol Oral Cir Bucal. 2017 Mar 1;22(2):e159-e166
pubmed: 28160585
J Ethnopharmacol. 2015 Sep 15;173:225-30
pubmed: 26102552
J Craniomaxillofac Surg. 2014 Jul;42(5):e281-3
pubmed: 24275482